Shares of IGC Pharma, Inc. (NYSEAMERICAN:IGC – Get Free Report) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.00 and traded as high as $0.38. IGC Pharma shares last traded at $0.36, with a volume of 160,873 shares trading hands.
IGC Pharma Trading Up 3.4 %
The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.14 and a current ratio of 2.38. The firm has a market capitalization of $19.52 million, a P/E ratio of -1.72 and a beta of 1.91.
IGC Pharma (NYSEAMERICAN:IGC – Get Free Report) last issued its earnings results on Thursday, August 10th. The construction company reported ($0.04) earnings per share for the quarter. IGC Pharma had a negative net margin of 860.24% and a negative return on equity of 64.87%. The business had revenue of $0.56 million during the quarter.
Hedge Funds Weigh In On IGC Pharma
IGC Pharma Company Profile
IGC Pharma, Inc, a clinical stage biotechnology company, engages in developing cannabinoid-based formulations for treating diseases and conditions, including Alzheimer's disease, dysmenorrhea, premenstrual syndrome, and chronic pain. The company has two investigational drug assets targeting Alzheimer's disease comprising IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63 that is in pre-clinical development.
- Five stocks we like better than IGC Pharma
- NYSE Stocks Give Investors a Variety of Quality Options
- These 3 Wood Stocks are about to go on Discount
- Where Do I Find 52-Week Highs and Lows?
- Same Coin, Different Sides: 2 Observability Stocks Reverse Ways
- What is Put Option Volume?
- 3 Stocks Awaiting Winter Winds of Opportunity
Receive News & Ratings for IGC Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IGC Pharma and related companies with MarketBeat.com's FREE daily email newsletter.